Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;43(43):3170-3183.
doi: 10.1038/s41388-024-03151-9. Epub 2024 Sep 10.

USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2

Affiliations

USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2

Jiming Chen et al. Oncogene. 2024 Oct.

Abstract

Post-translational modifications of proteins play a pivotal role in both the initiation and progression of ovarian cancer. Despite the recognition of USP33 as a significant factor in various cancers, its specific function and underlying mechanisms in ovarian cancer remain elusive. Proteomics and ubiquitinomics approaches were coupled to screen novel substrate proteins directly regulated by USP33. Our findings unveil that USP33 was observed to eliminate K27- and K48-linked ubiquitin chains from CBX2 at the K277 position. Notably, acetylation of CBX2 at K199, catalyzed by lysine acetyltransferase GCN5, was found to enhance its interaction with USP33, subsequently promoting further deubiquitination and stabilization. Functionally, our experiments demonstrate that USP33 significantly enhances ovarian cancer proliferation and metastasis in a CBX2-dependent manner. Furthermore, analysis revealed a direct positive correlation between the expression levels of USP33 and CBX2 proteins in human specimens, with elevated levels being associated with reduced survival rates in ovarian cancer patients. These findings elucidate the mechanism by which USP33 augments ovarian cancer progression through the stabilization of CBX2, underscoring the USP33-CBX2 axis as a promising therapeutic target in ovarian cancer management.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. https://doi.org/10.3322/caac.21763 . - DOI - PubMed
    1. Konstantinopoulos PA, Matulonis UA. Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023;4:1239–57. https://doi.org/10.1038/s43018-023-00617-9 . - DOI - PubMed
    1. Karimi F, Azadbakht O, Veisi A, Sabaghan M, Owjfard M, Kharazinejad E, et al. Liquid biopsy in ovarian cancer: advantages and limitations for prognosis and diagnosis. Med Oncol. 2023;40:265. https://doi.org/10.1007/s12032-023-02128-0 . - DOI - PubMed
    1. Geffen Y, Anand S, Akiyama Y, Yaron TM, Song Y, Johnson JL, et al. Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation. Cell. 2023;186:3945–67.e3926. https://doi.org/10.1016/j.cell.2023.07.013 . - DOI - PubMed - PMC
    1. Tang S. Protein modifications and diseases. J Cell Physiol. 2024;239:e31194 https://doi.org/10.1002/jcp.31194 . - DOI - PubMed

LinkOut - more resources